{"id":32419,"date":"2022-11-14T07:27:00","date_gmt":"2022-11-14T07:27:00","guid":{"rendered":"https:\/\/zeepedia.com\/?p=32419"},"modified":"2022-11-15T09:16:21","modified_gmt":"2022-11-15T09:16:21","slug":"xevudy","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/xevudy\/","title":{"rendered":"Xevudy &#8211; Sotrovimab uses, dose and side effects"},"content":{"rendered":"\n<p>500 mg\u00a0concentrate for\u00a0infusion solution, solution<br>sotrovimab<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Xevudy is and what it is used for<\/h2>\n\n\n\n<p>Judy contains the active substance sotrovimab.\u00a0Sotrovimab is a so-called\u00a0monoclonal\u00a0antibody, a type of\u00a0protein\u00a0designed to recognize a specific target of the SARS-CoV-2\u00a0virus\u00a0et that causes covid-19.<\/p>\n\n\n\n<p>Judy is used to treat covid\u201119 in adults and adolescents (from the age of 12 and weighing at least 40 kg).\u00a0Xevudy targets the spike\u00a0protein\u00a0that the\u00a0virus\u00a0uses to bind to cells, blocking the\u00a0virus\u00a0from entering the cell and multiplying.\u00a0By preventing the\u00a0virus\u00a0from multiplying in the body, Xevudy can help your body overcome\u00a0infection\u00a0and prevent you from becoming seriously ill.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What you need to know before you are given Xevudy<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not receive treatment with Xevudy<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to sotrovimab or any of the other ingredients of this medicine (listed in section 6).<\/li><li><strong>Talk to your doctor<\/strong>&nbsp;if you think this applies to you.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and precautions<\/h2>\n\n\n\n<p><strong>Allergic reactions<\/strong><\/p>\n\n\n\n<p>Xevudy can cause allergic reactions.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>See \u201cAllergic reactions\u201d in section 4.<\/li><\/ul>\n\n\n\n<p><strong>Infusion-related reactions<\/strong><\/p>\n\n\n\n<p>Xevudy can cause infusion-related reactions<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>See \u201cInfusion-related reactions\u201d in section 4.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Children and young people<\/h2>\n\n\n\n<p>Xevudy should not be given to children and adolescents under 12 years of age or who weigh less than 40 kg.<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and Xevudy<\/h2>\n\n\n\n<p><strong>Tell your doctor or pharmacist if you are taking<\/strong>, have recently taken, or might be taking other medicines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p>If you are\u00a0<strong>pregnant, think you may be pregnant,<\/strong>\u00a0or\u00a0are planning to have a baby,\u00a0<strong>consult your doctor<\/strong>\u00a0before being treated with Xevudy.\u00a0Your doctor will advise you whether the benefits of treatment with Xevudy outweigh any likely risks to you and your baby.<\/p>\n\n\n\n<p><strong>It is not known<\/strong>\u00a0whether the ingredients of Xevudy can pass into breast milk.\u00a0<strong>If you are breastfeeding, you must consult your doctor<\/strong>\u00a0before being treated with Xevudy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Driving ability and use of machinery<\/h2>\n\n\n\n<p>Xevudy is not expected to affect the ability to drive or use machines.<a><\/a><br><br><a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Xevudy is given<\/h2>\n\n\n\n<p><strong>The recommended&nbsp;dose&nbsp;for adults and<\/strong>&nbsp;adolescents (from the age of 12 and weighing at least 40 kg) is:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>500 mg (a&nbsp;vial&nbsp;).<\/li><\/ul>\n\n\n\n<p>This medicine is prepared into a solution and given as a drip (&nbsp;<em>infusion<\/em>&nbsp;) into a vein (&nbsp;intravenously&nbsp;) by a doctor or nurse.&nbsp;It takes 30 minutes to give the full&nbsp;dose of&nbsp;a medicine.&nbsp;You will be monitored during and at least 1 hour after you are given the treatment.<\/p>\n\n\n\n<p>&#8220;Information for healthcare professionals&#8221; below provides instructions for your doctor, pharmacist, or nurse on preparing and administering\u00a0an infusion\u00a0with Xevudy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause\u00a0side effects, although not everybody gets them.<\/p>\n\n\n\n<p><strong>Allergic reactions<\/strong><\/p>\n\n\n\n<p>Allergic reactions to Xevudy are&nbsp;<strong>common<\/strong>&nbsp;and may affect up to 1 in 10 people:<\/p>\n\n\n\n<p>In rare cases, these reactions can be serious (&nbsp;<em>anaphylaxis<\/em>&nbsp;) and may affect up to 1 in 1,000 people (&nbsp;<strong>rare<\/strong>&nbsp;).&nbsp;If you experience any of the following symptoms after treatment with Xevudy, you may have had an&nbsp;allergic reaction&nbsp;and should&nbsp;<strong>seek medical attention immediately<\/strong>&nbsp;:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>skin rash, similar to\u00a0hives\u00a0(\u00a0<em>hives<\/em>\u00a0) or\u00a0redness<\/li><li>itching<\/li><li>swelling, sometimes of the face or mouth (\u00a0<em>angioedema<\/em>\u00a0)<\/li><li>wheezing\/wheezing, coughing, or difficulty breathing<\/li><li>sudden dizziness or feeling weak (may lead to unconsciousness or fall)<\/li><\/ul>\n\n\n\n<p><strong>Infusion-related reactions<\/strong><\/p>\n\n\n\n<p>Allergy-like reactions when you receive an&nbsp;infusion&nbsp;are&nbsp;<strong>common<\/strong>&nbsp;and may affect up to 1 in 10 people.&nbsp;These usually develop within minutes or hours but may develop up to 24 hours after treatment or later.&nbsp;Possible symptoms are presented below.&nbsp;If you experience any of the following symptoms after treatment with Xevudy, you may have had an infusion-related reaction and should&nbsp;<strong>seek medical attention immediately:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>redness<\/li><li>overindulge<\/li><li>fever<\/li><li>breathing difficulties<\/li><li>rapid heartbeat<\/li><li>blood pressure drop<\/li><\/ul>\n\n\n\n<p><strong>Other\u00a0side effects\u00a0are<\/strong><\/p>\n\n\n\n<p><strong>Rare<\/strong>&nbsp;(may affect up to 1 in 100 people)<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>shortness of breath (&nbsp;dyspnea&nbsp;)<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">How to store Xevudy<\/h2>\n\n\n\n<p>Healthcare professionals caring for you are responsible for storing this medicine and disposing of the unused product properly.<\/p>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n<p>Do not use this medicine if the expiry date has passed.&nbsp;The expiry date is indicated on the label and carton after EXP.<\/p>\n\n\n\n<p>Do not freeze.<\/p>\n\n\n\n<p>Before dilution:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>store in a refrigerator (2 \u00b0C\u2013 8 \u00b0C).<\/li><li>stored in the original packaging.&nbsp;Light sensitive.<\/li><\/ul>\n\n\n\n<p>After dilution, this medicine is intended for immediate use.&nbsp;If immediate&nbsp;administration&nbsp;is not possible after dilution, the diluted solution can be stored at room temperature (up to 25 \u00b0C) for up to 6 hours or in a refrigerator (2 \u00b0C \u2013 8 \u00b0C) for up to 24 hours from the time of dilution until the end of&nbsp;administration&nbsp;one.<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contents of the packaging and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Contents declaration<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>The active substance is sotrovimab.\u00a0One\u00a0vial\u00a0contains 500 mg sotrovimab in 8 ml concentrate.<\/li><li>Other ingredients: histidine, histidine monohydrochloride, sucrose, polysorbate 80, methionine, and water for injections.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The appearance of the medicine and the contents of the package<\/h2>\n\n\n\n<p>Xevudy is a clear, colorless, or yellow to brown liquid supplied in a single-use\u00a0vial\u00a0with a rubber stopper and sealed with a flip-off aluminum cap.\u00a0Each carton contains one\u00a0vial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing authorization holder and manufacturer<\/h2>\n\n\n\n<p><strong>Marketing Authorisation Holder<\/strong><\/p>\n\n\n\n<p>GlaxoSmithKline Trading Services Limited<\/p>\n\n\n\n<p>12 Riverwalk<\/p>\n\n\n\n<p>Citywest Business Campus<\/p>\n\n\n\n<p>Dublin 24<\/p>\n\n\n\n<p>Ireland<br><\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>GlaxoSmithKline Manufacturing SpA<\/p>\n\n\n\n<p>Strada Provinciale Atlanta, 90,<\/p>\n\n\n\n<p>43056 San Polo di Torrile, Parma<\/p>\n\n\n\n<p>Italy<\/p>\n\n\n\n<p>For further information about this medicinal product, contact the representative of the marketing authorization holder:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Belgi\u00eb\/Belgique\/Belgien<\/strong>GlaxoSmithKline Pharmaceuticals sa\/nvTel\/Tel: + 32 (0) 10 85 52 00<\/td><td><strong>Lithuania<\/strong>GlaxoSmithKline Trading Services LimitedPhone: + 370 80000334<\/td><\/tr><tr><td><strong>Bulgaria<\/strong>GlaxoSmithKline Trading Services LimitedTel.: + 359 80018205<\/td><td><strong>Luxembourg\/Luxembourg<\/strong>GlaxoSmithKline Pharmaceuticals sa\/nvBelgique\/BelgiumTel\/Tel: + 32 (0) 10 85 52 00<\/td><\/tr><tr><td><strong>Czech Republic<\/strong>GlaxoSmithKline, Serophene: + 420 222 001 111cz.info@gsk.com<\/td><td><strong>Magyarorsz\u00e1g<\/strong>GlaxoSmithKline Trading Services Limited.Phone: + 36 80088309<\/td><\/tr><tr><td><strong>Denmark<\/strong>GlaxoSmithKline Pharma A\/SPhone: + 45 36 35 91 00dk-info@gsk.com<\/td><td><strong>Malta<\/strong>GlaxoSmithKline Trading Services Limited.Phone: + 356 80065004<\/td><\/tr><tr><td><strong>Deutschland<\/strong>GlaxoSmithKline GmbH &amp; Co.&nbsp;KGTel.: + 49 (0)89 36044 8701product.info@gsk.com<\/td><td><strong>The Netherlands<\/strong>GlaxoSmithKline BVPhone: + 31 (0)33 2081100<\/td><\/tr><tr><td><strong>Estonia<\/strong>GlaxoSmithKline Trading Services Limited.Phone: + 372 8002640<\/td><td><strong>Norway<\/strong>GlaxoSmithKline iPhone: + 47 22 70 20 00<\/td><\/tr><tr><td><strong>Greece<\/strong>GlaxoSmithKline \u039c\u03bf\u03bd\u03bf\u03c0\u03c1\u03bf\u03c3\u03c9\u03c0\u03b7 AEBETel: + 30 210 68 82 100<\/td><td><strong>Austria<\/strong>GlaxoSmithKline Pharma GmbHTel: + 43 (0)1 97075 0at.info@gsk.com<\/td><\/tr><tr><td><strong>Spain<\/strong>GlaxoSmithKline, SAPhone: + 34 900 202 700es-ci@gsk.com<\/td><td><strong>Polish<\/strong>GSK Services Sp.&nbsp;z o. oTel.: + 48 (0)22 576 9000<\/td><\/tr><tr><td><strong>France<\/strong>Laboratory GlaxoSmithKlineTel: + 33 (0)1 39 17 84 44diam@gsk.com<\/td><td><strong>Portugal<\/strong>GlaxoSmithKline \u2013 Produtos Farmac\u00eauticos, Lda.Phone: + 351 21 412 95 00FI.PT@gsk.com<\/td><\/tr><tr><td><strong>Hrvatska<\/strong>GlaxoSmithKline Trading Services LimitedPhone: +385 800787089<\/td><td><strong>Romania<\/strong>GlaxoSmithKline Trading Services LimitedPhone: + 40800672524<\/td><\/tr><tr><td><strong>Ireland<\/strong>GlaxoSmithKline (Ireland) LimitedPhone: + 353 (0)1 4955000<\/td><td><strong>Slovenija<\/strong>GlaxoSmithKline Trading Services LimitedPhone: + 386 80688869<\/td><\/tr><tr><td><strong>Iceland<\/strong>Vistor hf.Telephone: + 354 535 7000<\/td><td><strong>Slovenian Republic<\/strong>GlaxoSmithKline Trading Services LimitedPhone: + 421 800500589<\/td><\/tr><tr><td><strong>Italy<\/strong>GlaxoSmithKline SpAPhone: + 39 (0)45 7741111<\/td><td><strong>Finland\/Finland<\/strong>GlaxoSmithKline OyPhone\/Tel: + 358 (0)10 30 30 30<\/td><\/tr><tr><td><strong>Cyprus<\/strong>GlaxoSmithKline Trading Services LimitedTel: + 357 80070017<\/td><td><strong>Sweden<\/strong>GlaxoSmithKline ABPhone: + 46 (0)8 638 93 00info.produkt@gsk.com<\/td><\/tr><tr><td><strong>Latvia<\/strong>GlaxoSmithKline Trading Services LimitedPhone: + 371 80205045<\/td><td><strong>Great Britain (Northern Ireland)<\/strong>GlaxoSmithKline Trading Services LimitedPhone: + 44 (0)800 221441customercontactuk@gsk.com<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Xevudy contains the active substance sotrovimab.\u00a0Sotrovimab is a so-called\u00a0monoclonal\u00a0antibody\u00a0, a type of\u00a0protein\u00a0designed to recognize a specific target on the SARS-CoV-2\u00a0virus\u00a0et that causes covid-19.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,22504],"tags":[28018,28022,28014,28016,28015,28020,28017,28021,28019,28023],"class_list":["post-32419","post","type-post","status-publish","format-standard","hentry","category-medicines","category-x","tag-benefits-of-sotrovimab","tag-benefits-of-xevudy","tag-sotrovimab","tag-sotrovimab-side-effects","tag-what-is-sotrovimab","tag-what-is-xevudy","tag-what-sotrovimab-is-used-for","tag-what-xevudy-is-used-for","tag-xevudy","tag-xevudy-side-effects"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/32419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=32419"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/32419\/revisions"}],"predecessor-version":[{"id":32926,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/32419\/revisions\/32926"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=32419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=32419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=32419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}